We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
Read MoreHide Full Article
Roche Holdings AG (RHHBY - Free Report) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab. The data were published in The New England Journal of Medicine (NEJM).
The study evaluated once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with hemophilia A with inhibitors. The primary endpoint showed a clinically meaningful and statistically significant reduction in treated bleeds of 87% with emicizumab prophylaxis compared to on-demand bypassing agents (BPAs). In addition, all 12 secondary endpoints were positive, including a statistically significant reduction of 79% in treated bleeds in a subset of patients comparing two prophylaxis regimens (emicizumab and BPAs).
The data from the study, HAVEN 1 as well as the interim analysis of the phase III study, HAVEN 2, of emicizumab in children will be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress.
The data from both studies have been submitted to the FDA and the EMA for approval. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with hemophilia A with inhibitors in Sep 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche’s share price shows that the company has underperformed the Zacks classified industry in the last year. The stock lost 4.6% compared with the Large Cap Pharmaceuticals industry’s gain of 1.2%.
Along with emicizumab, Roche’s hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie (ABBV - Free Report) along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Last week, Shire filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Enzo Biochem’s loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 55.83%. Its shares have moved up 59.9% so far this year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
Roche Holdings AG (RHHBY - Free Report) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab. The data were published in The New England Journal of Medicine (NEJM).
The study evaluated once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with hemophilia A with inhibitors. The primary endpoint showed a clinically meaningful and statistically significant reduction in treated bleeds of 87% with emicizumab prophylaxis compared to on-demand bypassing agents (BPAs). In addition, all 12 secondary endpoints were positive, including a statistically significant reduction of 79% in treated bleeds in a subset of patients comparing two prophylaxis regimens (emicizumab and BPAs).
The data from the study, HAVEN 1 as well as the interim analysis of the phase III study, HAVEN 2, of emicizumab in children will be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress.
The data from both studies have been submitted to the FDA and the EMA for approval. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with hemophilia A with inhibitors in Sep 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche’s share price shows that the company has underperformed the Zacks classified industry in the last year. The stock lost 4.6% compared with the Large Cap Pharmaceuticals industry’s gain of 1.2%.
Along with emicizumab, Roche’s hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie (ABBV - Free Report) along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Last week, Shire filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Zacks Rank and Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the health care sector is Enzo Biochem, Inc. (ENZ - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss estimates have narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 55.83%. Its shares have moved up 59.9% so far this year.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>